Eye Allergy Treatment Market Size

Eye Allergy Treatment Market Growth Projections and Opportunities

The largest share of the global eye allergy treatment market, comprising 69.00% in 2017, belonged to the seasonal and perennial allergic conjunctivitis segment. This segment, valued at USD 1,185.42 million in 2017, is predicted to grow at a CAGR of 5.33% during the forecast period. The prevalence of seasonal and perennial allergic conjunctivitis is a major factor contributing to its significant market share. Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are the most common types of allergic conjunctivitis, affecting about 98% of people experiencing eye allergies. According to the Virtual Medical Centre and The College of Optometrists, SAC is one of the most widespread eye problems, impacting approximately one-fifth of adults.

The vernal keratoconjunctivitis segment, valued at USD 215.13 million in 2017, is anticipated to be the second-largest lucrative segment, showing a projected CAGR of 5.31%. The growth in this segment is attributed to the increasing cases of vernal keratoconjunctivitis, especially among males. According to the National Center for Biotechnology Information (NCBI), this condition is most prevalent among boys in warm, dry, subtropical regions such as the Mediterranean, the Middle East, Central and West Africa, Latin America, and Asian countries like Japan, Thailand, and India. NCBI also notes a male-to-female ratio of 3.2:1 in patients under 20 years of age for vernal keratoconjunctivitis.

In contrast, the atopic keratoconjunctivitis segment is expected to register the highest CAGR of 5.34%. This suggests a significant growth trend in the treatment of atopic keratoconjunctivitis compared to other segments.

The global eye allergy treatment market is categorized based on types, including seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis.

The giant papillary conjunctivitis segment is projected to have the smallest market share during the forecast period. This is attributed to its limited impact, primarily affecting individuals who wear contact lenses. As a result, the prevalence of giant papillary conjunctivitis is expected to be lower compared to other segments.

In summary, the global eye allergy treatment market is dominated by the seasonal and perennial allergic conjunctivitis segment, driven by its high prevalence. The vernal keratoconjunctivitis segment follows as the second-largest, with increasing cases among the male population. The atopic keratoconjunctivitis segment is expected to exhibit the highest growth, while giant papillary conjunctivitis is anticipated to have the least impact due to its association with contact lens wearers.